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ABSTRACT: Intellectual disability (ID) is a heterogeneous
disorder with an unknown molecular etiology in many
cases. Previously, X-linked ID (XLID) studies focused on
males because of the hemizygous state of their X chromo-
some. Carrier females are generally unaffected because of
the presence of a second normal allele, or inactivation of
the mutant X chromosome in most of their cells (skew-
ing). However, in female ID patients, we hypothesized
that the presence of skewing of X-inactivation would be
an indicator for an X chromosomal ID cause. We ana-
lyzed the X-inactivation patterns of 288 females with ID,
and found that 22 (7.6%) had extreme skewing (>90%),
which is significantly higher than observed in the general
population (3.6%; P = 0.029). Whole-exome sequenc-
ing of 19 females with extreme skewing revealed causal
variants in six females in the XLID genes DDX3X, NHS,
WDR45, MECP2, and SMC1A. Interestingly, variants
in genes escaping X-inactivation presumably cause both
XLID and skewing of X-inactivation in three of these pa-
tients. Moreover, variants likely accounting for skewing
only were detected inMED12, HDAC8, and TAF9B. All
tested candidate causative variants were de novo events.
Hence, extreme skewing is a good indicator for the pres-
ence of X-linked variants in female patients.
Hum Mutat 00:1–8, 2016. C© 2016 Wiley Periodicals, Inc.
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Introduction
Intellectual disability (ID) is a very clinically and genetically het-
erogeneous disorder with a prevalence of 2%–3% in the general
population of developed countries [Leonard andWen, 2002; Ropers
andHamel, 2005]. ID can be the solemajor clinical feature observed
(non-syndromic ID) but can also be associated with other clinical
features (syndromic ID). In about 40% of these cases, the etiol-
ogy remains unknown. Since 30%more males than females present
with ID [Herbst and Miller, 1980] and because there is an overrep-
resentation of the expression of X chromosomal genes in the central
nervous system in comparison with autosomal genes [Nguyen and
Disteche, 2006], the search for ID associated genes initially focused
on the X chromosome (X-linked ID, XLID) [de Brouwer et al.,
2007]. To date, over 100 XLID genes have already been identified
[Piton et al., 2013]. Traditionally, XLID studies focused on males
since X-linked mutations in males are always expressed because of
the hemizygous state of the X chromosome. In females, two X chro-
mosomes are present and X-inactivation of one of them takes place
in every cell. Females can be carrier of an X-linked mutation but
are generally not or mildly affected because of the compensation by
their second normal allele or because of inactivation of themutant X
chromosome in most of their cells (skewing). Therefore, in contrast
to this study, mutations in X-linked genes are generally not searched
for in female ID patients unless structural defects (e.g., X-autosome
translocations) on the X chromosome are detected.
The process of X-inactivation entails the random transcriptional
silencingof oneof the twoXchromosomespresent in female somatic
cells and takes place during the blastocyst stage of early development
[Barakat et al., 2011; Belmont 1996]. Once X-inactivation is initi-
ated, the chosen X chromosome remains inactive for the rest of that
cell’s life and the X-inactivation pattern is passed on to its daughter
cells. Various epigenetic mechanisms are involved in the inactiva-
tionprocess, includingDNAmethylation,XISTRNA-mediatedgene
silencing, and chromatin modification [Barakat et al., 2010]. How-
ever, not all genes on the inactivated X chromosome are completely
silenced. About 15% of human genes “escape” from X-inactivation
and the proportion of genes that escape can vary between different
regions of the X chromosome. An additional 10% of X-linked genes
show variable patterns of inactivation and are expressed to different
extents from inactive X chromosomes [Carrel and Willard 2005].
Some of the genes that escape have a Y-linked paralog and therefore
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these genes behave as autosomal genes [Disteche 1997]. In about
14% of females, skewing of X-inactivation occurs [Amos-Landgraf
et al., 2006]. This refers to the situation where one X chromo-
some becomes preferentially inactivated in >80% of all somatic cells
[Nesterova et al., 2003]. The current cut off for biologically signifi-
cant and potentially clinically relevant skewing is often set at >90%,
but to avoid confusion, this threshold is referred to as “extreme”
skewing of X-inactivation in this study. In the general population,
the X-inactivation ratio is subjected to a Gaussian distribution and
extreme skewing was reported to be present in 3.6% of females
[Amos-Landgraf et al., 2006]. However, X-inactivation is measured
in blood cells andmight thus not always reflect the situation in other
somatic cells and tissues.
Skewing of X-inactivation can occur by chance, but can also
be caused by primary or secondary stochastic or genetic processes
[Morey and Avner 2011]. In primary skewing, the inactive X chro-
mosome is chosen before silencing is initiated [Morey and Avner
2011]. An example of primary skewing is a potential harmful mu-
tation in XIST (MIM# 314670) [Nesterova et al., 2003], which pre-
cludes the cell from silencing thatX chromosome carrying themuta-
tion. However, mutations in XIST are very rare. The most common
cause of secondary skewing is post-inactivation cell selection, due
to an X chromosomemutation that affects cell proliferation [Morey
and Avner 2011]. Therefore, skewed X-inactivation may point to a
carrier status of an X-linked mutation.
In this study, we investigated skewing of X-inactivation as a
screening method to detect (novel) XLID mutations in female pa-
tients. In femaleswith skewing, the sameparentally inheritedXchro-
mosome will be active in almost all of their (blood) cells. Therefore,
if a detrimental mutation is present on the active X chromosome,
it will be fully expressed. This means that the masking effect estab-
lished by random X-inactivation would no longer be present and
we expect the female patient to manifest the full blown phenotype.
This is similar to the situation in males who have no choice but to
express their single X chromosome. In this report, we investigated
the exomes of 19 female patients with ID and >90% skewing us-
ing whole-exome sequencing (WES). We detected variants in the
ID genes DDX3X (MIM# 300160), NHS (MIM# 300457), SMC1A
(MIM#300040),WDR45 (MIM#300526),MECP2 (MIM#300005),
MED12 (MIM# 300188), HDAC8 (MIM# 300269), TAF9B (MIM#
300754), EP300 (MIM# 602700), and SYNGAP1 (MIM# 603384)
that could be responsible for the patients ID phenotypes, for skew-
ing or for both.
Materials and Methods
Samples
Genomic DNA samples from 223 female patients with sporadic
and syndromic ID were obtained from the Center for Human
Genetics (Leuven), and 93 samples were received from genetic cen-
ters outside Belgium. Only female patients with extreme skewed X-
inactivation ratios (>90%)were selected for further analysis (N=22).
We focused on sporadic individuals because families with multiple
affected females more likely have an autosomal cause of their ID,
and we selected patients with more severe syndromic phenotypes
because of the higher chance of finding genetic defects when com-
pared with more subtly affected patients with isolated ID [Ropers
2010]. Finally, because of an increase in the degree of skewing with
age [Busque et al., 1996], only females of 35 years or younger were
included. The screening protocols were approved by the appropri-
ate Institutional Review Board of the respective UniversityHospitals
and informed consent was obtained from the parents of the affected
patients.
Genomic DNA from patients, their parents, if available, and con-
trol females was isolated from peripheral blood according to stan-
dard procedures and stored at 4°C. Primer sequences are provided
in Supp. Table S1.
X-Inactivation
Lymphocyte-derived genomic DNA was subjected to the stan-
dard androgen receptor (MIM# 313700) assay to determine X-
inactivation ratios [Allen et al., 1992]. In non-informative caseswith
homozygous AR alleles, the more recently developed PGK1 (MIM#
311800) [van Kamp et al., 1991] and PCSK1N (MIM# 300399)
[Bertelsen et al., 2011] X-inactivation assays were used.
XIST Sequencing and X Array-CGH
PCR followedby Sanger sequencingwas performedon thehighest
conserved regionof the14kbXISTgene,whichcontains theminimal
promoter region and the beginning of exon 1, covering a total region
of 3.2 kb in size (ChrX: 73,069,528-73,072,728; UCSC Hg19). Five
overlapping PCR products were generated and Sanger sequenced.
Only patients with >95% X chromosome inactivation (XCI) were
analyzed becausemutations inXIST are expected to lead to complete
skewing of X-inactivation. Oligo-based X chromosome array-CGH
analysis was performed as described in Fieremans et al. (2015).
Whole-Exome Sequencing
For seven samples, exome sequencing was done at the Ge-
nomics Core Facility, KU Leuven, Leuven, Belgium. Exome capture
was performed with the SeqCap EZ Human Exome Library v3.0
(NimbleGen, Madison, WI). These samples were subsequently se-
quenced in a paired end 101 bp run on a HiSeq 2000 instrument
(Illumina, San Diego, CA). Another 12 patients were whole-exome
sequenced at Baylor College of Medicine as published [Lupski et al.,
2013; Yang et al., 2014]. Data analysis was done using an in-house
pipeline of the Genomics Core Facility, KU Leuven. For patients
1, 2, and 8, reads were mapped with BWA version 0.6.2 and BWA
aln options–q15 [Li andDurbin 2010], thenmerged, de-duplicated,
realigned, and recalibrated with GATK [DePristo et al., 2011]. Vari-
ants were called with Unified Genotyper (GATK version 2.4.9). For
patients 3 and 7, BWA version 0.7.5a and BWA mem options–q15
were used together with GATK version 3.1.1. Haplotype Caller was
used for variant calling. For the remaining patients 4, 5, 6, 9, and 10,
BWA version 0.7.8 and BWA mem options–q15 were used together
with GATK version 3.2.2. Again, Haplotype Caller was used for
variant calling. All variants were annotated using Annovar version
11-02 2013 (http://www.openbioinformatics.org/annovar/ [Wang
et al., 2010]). All non-exonic, non-splice site and synonymous vari-
ants, as well as segmental duplications were excluded. Additionally,
variants with a frequency 0.05 and 0.95 in the 1000 genomes
project (http://www.1000genomes.org) and in less than 1% of sam-
ples in the NGS-Logistics database (https://ngsl.esat.kuleuven.be/)
[Ardeshirdavani et al., 2014]were kept. TheNGS-Logistics Standard
Min Confidence Threshold For Calling was set at 50, Standard Min
ConfidenceThreshold ForEmitting at 0 anddcov at 200. For autoso-
mal variants, only those in known IDgenes [Gilissen et al., 2014] and
with a frequency0.01 or0.99 in the 1000 genomes project were
included. Variants that were predicted to be benign by the Clinvar
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Table 1. Number of Females with Preferential X-Inactivation
80% and 90% Skewing in the General Population (Amos-
Landgraf et al., 2006) Compared to our Patient Population
Controls ID females
(n = 415) (n = 288)
# % # %
Preferential X-inactivation
80%
59 14.2 52 18.06
Preferential X-inactivation
90% (skewing)
15 3.60 22 7.6
n, total number of females; #, number of females in group.
database (http://www.ncbi.nlm.nih.gov/clinvar/) were excluded.
Nonsynonymous variants were also evaluated based on predicted
pathogenicity using in silico analysis including SIFT [Kumar et al.,
2009], Poly Phen-2 [Adzhubei et al., 2010], PhyloP [Pollard et al.,
2010],GERP++ [Cooper et al., 2005], LRT [Chun andFay 2009], and
Mutation Taster [Schwarz et al., 2014]. Gene function and available
genotype–phenotype correlationswere used to further prioritize the
variants (NCBI, OMIM, Pubmed). Variant confirmation was done
by PCR and Sanger sequencing in the patients and their parents if
DNA was available. X-linked variants that were paternally inher-
ited were excluded from further analysis. Autosomal variants that
were inherited from either parent were also excluded if no other
potentially damaging variants were detected in that gene. Escape
of X-inactivation was evaluated based on the study of Carrel and
Willard [Carrel and Willard 2005]. Variants reported in this study
havebeen submitted todbVar (http://www.ncbi.nlm.nih.gov/dbvar)
with entry SUB1311146.
Expression Analysis
Total RNA was extracted from white blood cells or low-passage
Epstein Barr virus-transformed peripheral blood lymphocytes
(EBV-PBLs). Expression analysis was performed on cDNA by PCR
and Sanger sequencing as described previously [Froyen et al., 2012].
For X-linked variants, the expression level, or lack of expression
could serve as an indication of whether the variant was located on
the predominantly active or inactive X chromosome, respectively.
Results
X-Inactivation Analysis
In total, 316 female patients with sporadic and syndromic ID
were subjected to the AR X-inactivation assay. In nine out of 37
females who were homozygous at the AR locus, the PGK1 and/or
PCSK1N assays were informative. From the 288 informative female
patients, 22 (7.6%) had extreme skewing. The X-inactivation results
are summarized in Table 1 and Supp. Figure S1. Compared with a
set of 415 control females reported by Amos-Landgraf et al. (2006),
there is a significantly higher prevalence of extreme skewing in the
female ID patient cohort (P value = 0.029). The control group used
by Amos-Landgraf and colleagues was subjected to theAR assay and
consisted mostly of women of child-bearing age and a few younger
adults older than 13 years [Amos-Landgraf et al., 2006]. This is
similar in constitution and age distribution to our cohort of female
patients under 35 years of age.
Mutation Detection by Exome Sequencing
From the 22 female patients with extreme skewing, 19 with a suf-
ficient amount of DNA available were subjected to WES. In 10 out
of 19 patients, a total of 11 likely pathogenic variants were detected,
nine on the X chromosome, and two on autosomes. All variants
were confirmed by Sanger sequencing (Supp. Table S2), were absent
in the NGS-Logistics databank, and were predicted to be detrimen-
tal by online prediction programs (Table 2). Moreover, all of these
variants, besides the indel in TAF9B, were located in known ID
genes. If the same variant had been reported previously in dbSNP
(http://www.ncbi.nlm.nih.gov/SNP/) or in the literature, this ob-
servation is depicted in the “Remarks” column of Table 2. The XCI
pattern of each patient and the major clinical features are also in-
cluded. In case parental DNAwas available, themode of inheritance,
XCI pattern of the mother and whether the predominantly active
or inactive X of the mother (based on the AR/PGK1 XCI assays)
was inherited by the daughter, was also determined (Table 2 and
Supp. Table S2). Information on whether these variants are located
in genes that escape X-inactivation is provided and, where available,
patient cDNA was used to determine if the variant was presum-
ably located on the predominantly active or inactive X chromosome
(Table 2 and Supp. Table S2). The most important clinical features
are reported in Table 2. Additional relevant clinical information as
well as the detected variants is presented below. Family or individual
history is only mentioned if relevant. Oligo-based X array results
were normal for all 10 patients.
Patient 1 had severe ID, with ataxic gait. Biometry with weight
and head circumference is between p3 and p10 and her height
is p25–50. She had brachycephaly, prominent eyes, protrud-
ing ears, a wide mouth, and a cleft uvula. She previously had
surgery for vesicoureteral reflux. WES detected a nonsynonymous
(NM 001193417:p.G286S) variant in the escape gene DDX3X that
was absent in hermother. DNA from the father was not available but
it is rather unlikely that he would be a carrier as males withDDX3X
variants are reported to present with ID [Snijders Blok et al., 2015].
Patient 2 had mild to moderate ID and hypotonia. During ges-
tation, intrauterine growth restriction was noted. At birth, she
weighed 2,385 g, her head circumference was 31 cm, and her length
was 46 cm. Autonomous walking was acquired at 18 months and
speech at 4 years. Besides dysmorphic facial features (Supp. Fig. S2),
other anomalies include short stature, failure to thrive (height cen-
tile 10, weight <3rd centile), slender fingers, hirsutism in face and
trunk, low posterior hairline, pes cavus with hallux valgus, and
sub-clinical hypothyroidism. MRI, EEG, and mutation screening of
NIPBL (MIM# 608667) were negative. WES revealed a de novo stop
variant (NM 001193417:p.G177X) in DDX3X. Only the reference
G allele was present at cDNA level (Supp. Table S2).
Patient 3 had a mild Cornelia de Lange syndrome (MIM#
122470) phenotype (Supp. Fig. S3). Her clinical features are listed
in Supp. Table S3. In patient 3, a de novo recurrent SMC1A vari-
ant (NM 006306:p.I784T) was detected. SMC1A partially escapes
X-inactivation and at cDNA level both alleles were present although
the variant allele was present at a lower level than thewild-type allele
(Supp. Table S2).
Patient4was clinically examined at the age of 29 years. She had se-
vere ID.Herweight was 34 kg and she had short stature with a height
of 145 cm. She also presented with pronounced hyperkyphosis with
the lower segment at 78 cm. Her head circumference was 52.4 cm.
Additional features include low implanted ears and small hands and
feet with proximally implanted thumbs. She steps with assistance
and showed progressive spasticity of the lower limbs with clonus
and hypotrofy. A CT scan of her brain at age 31 revealed increased
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Table 2. Summary of Results for the 11 Candidate Variants Detected by WES in 19 Female ID Patients with Extreme Skewing
X-linked genes are indicated in bold; ID, intellectual disability; XCI, X chromosome inactivation; mat/pat, maternally/paternally inherited predominantly inactivated X chro-
mosome; XLID, X-linked ID; NR, not reported; ns, nonsynonymous; fr, frameshift; del, deletion; ins, insertion; stop, stop variant; C, conserved; /, not applicable; D, damag-
ing/deleterious/disease causing; T, tolerated; P, possibly damaging; A, disease automatic; Xi, inactive X; Xa, active X; ASD, autism spectrum disorder; OFC, occipitofrontal head
circumference.
density of the pedunculi. WES revealed a de novo frameshift variant
(NM 001029896:p.T260Lfs∗27) in WDR45, a gene that does not
escape X-inactivation. At cDNA level, the mutant allele was almost
exclusively used (Supp. Table S2).
Patient 5 had mild ID, autism spectrum disorder, and microph-
thalmia. She had dental surgery for correction of supernumerary
enclosed elements (19/29/49) at the age of 10 weeks, which was
complicated by a brief cardiac arrest. When seen at the age of
36 years, she showed a phenotype consistent with a diagnosis of
Nance-Horan syndrome, which was not diagnosed clinically. Her
teeth were long and partly tulip shaped. Additional features in-
cluded prominent low-set ears, a flat midface, a long philtrum, and
a broad lower part of her thorax. WES detected a de novo stop
variant (NM 001136024:p.Q55X) in NHS that partially escapes X-
inactivation.
Patient 6 was first seen at 53 years. She could walk at a
younger age but there was no relevant further information on
her individual history. Patient 6 harbors a recurrent stop variant
(NM 004992:p.R294X) inMECP2, reported 216 times in RettBASE
and known as a pathogenic variant in dbSNP (rs61751362).
Patient 7 was diagnosed with autism spectrum disorder and se-
vere ID. Shehad infantile scoliosis.Developmental delaywasfirst no-
ticed around the age of 6–9months.Her first stepswere at 22months
and her first words at 3 years. She presented with clinodactyly of
the fifth fingers, short fifth toes, small dorsally rotated ears, sparse
lateral eyebrows, deep set eyes, and short upper limbs. WES re-
vealed a nonsynonymous de novo variant (NM 005120:p.R521H)
inMED12. At cDNA level, only the reference G-allele was present.
Patient 8 (Supp. Fig. S4) had synophrys, micrognathia, growth
delay, postnatal low weight and height (<p3), gastroesophageal re-
flux, hypotonia, seizures (hypertonic crisis), moderate ID with lan-
guage delay, and autistic traits. The patient does not have features
consistent with a phenotype reported for patients withHDAC8mu-
tations that result in Cornelia De Lange syndrome (MIM# 300269).
MRI and EEG results were normal. Patient 8 carries a nonsynony-
mous de novo variant (NM 018486:p.G320R) in HDAC8, located
at Xq13.1. At cDNA level, only the reference G-allele was present
(Supp. Table S2). Interestingly, this exact variant was reported pre-
viously in a severely affected male patient [Deardorff et al., 2012].
Patient 9 presented with mild developmental delay. At the age
of 16 months, she weighed 8.6 kg (P3), had a body length of
72 cm (<P3), and her head circumference was 44 cm (<P3). She
had trigonocephaly and an asymmetrical face. She had a large nae-
vus flammeus in the neck, the roof of her nose and upper lip, which
disappeared gradually. She has a broad nasal bridge with hyper-
telorism, an antimongoloid eye slant, narrow eye slits, and a long
hypoplastic philtrum.Her earswere dysplastic and therewas a crease
in her left earlobe. She had syndactyly of her feet (IIe and IIIe radius).
At the age of 4 years and 5months, she weighed 16 kg (P25) and had
a head circumference of 47.5 (<P3). She is a calm and cheerful child
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and can only speak a few words and sentences. Her skin was dry and
prone to eczema. Discrete lines of Blashko were visible on her upper
left arm. Her hands were small and she has interdigital webbing.
Karyotyping and mutation analysis of CREBBP were normal. NMR
of the brain and 1 Mb molecular karyotyping were normal as well.
This patient harbors an in-frame deletion of 12 nucleotides in EP300
(NM 001429:p.2189 2193del) located on chromosome 22. Parental
DNA was unavailable.
Patient 10 was diagnosed with nonsyndromic mild to moderate
ID and psychiatric problems (psychosis). WES revealed a nonsyn-
onymous variant (NM 006772:p.S1165L) in SYNGAP1 on chromo-
some 6 as well as an indel (NG 012570:g.7766 7770delinsAA) in
TAF9B, located at Xq21.1. Parental DNA was unavailable.
XIST Sequencing
For six patients with 95% skewing and for whom sufficient
DNA was available, we also performed XIST sequence analysis. No
variants that likely could lead to severe skewing were detected (data
not shown).
Discussion
We hypothesized that extreme skewing of X-inactivation (>90%)
is an indicator for the underlying genetic defect to be located on the
X chromosome. The observation of a twofold increased prevalence
of extreme skewing in our female ID patient population compared
with the control female cohort suggests that in approximately half
of our female patients who demonstrated extreme skewing, we can
expect an X-linked cause for ID that is related to skewing. Our
hypothesis is supported by the identification of 11 X-linked variants
in 19 female patients ofwhich at least sixwere causal variants present
in known XLID genes. These variants were divided into different
categories based on whether they are likely to cause ID, skewing of
X-inactivation, or both (Table 2). A detailed discussion of the results
and the relevant literature can be found in the Supp. Discussion.
Variants that Likely Cause XLID and Skewing
DDX3X escapes X-inactivation and therefore, the variants ob-
served (p.G286S and p.G177X in patients 1 and 2, respectively) can
cause ID irrespective of being located on the active or inactive X
chromosome. Mutations in DDX3X are predicted to be responsible
for 1%–3% of unexplained ID in female patients, probably through
haploinsufficiency [Snijders Blok et al., 2015]. Interestingly, Sni-
jders Blok et al. (2015) also reported that seven out of 15 females
with DDX3Xmutations and ID had almost complete skewing of X-
inactivation (>95%), which is much higher than would be expected
simply by chance. In patient 3, a de novo SMC1A variant (p.I784T)
was detected. SMC1A is reported to partially escape X-inactivation
and two other females with ID were reported with the same variant
[Gervasini et al., 2013; Limongelli et al., 2010]. In both, the variant
allele expression was roughly 50% lower than that of the wild-type
allele. Importantly, our cDNA expression data in patient 3 suggested
a similar trend (Supp. Table S2). Besides their similar clinical char-
acteristics, all three females had extreme skewing against themutant
X chromosome in blood cells.
In patient 4, a de novo frameshift variant (p.T260Lfs∗27)
was detected in WDR45. Mutations in this gene result in beta-
propeller protein-associated neurodegeneration (MIM# 300894)
[Haack et al., 2012]. At the cDNA level the mutant allele was al-
most exclusively expressed in our female patient. Interestingly, in
lymphoblastoid cell lines derived from WDR45 mutation carrying
female patients described in the literature, 4 out of 5 subjects also
exclusively expressed the mutant transcript [Saitsu et al., 2013].
Furthermore, 7 out of 17 female patients had XCI patterns above
90:10 in peripheral blood. This WDR45 variant could therefore be
an example of 1 “hit” in a non-escape gene causing secondary skew-
ing, although the possible involvement of WDR45 mutations in
skewing remains to be further elucidated. An overview of the likely
pathogenic variants detected in WDR45 is listed in Supp. Table S4.
In these four patients (1–4), the cause for ID appears to be directly
related to skewingand thereforeonlyone“hit”was sufficient to cause
both ID and skewing. Interestingly, three out of four suggested “one-
hit” variantswere located in escape genes (DDX3X andSMC1A) thus
suggesting that detrimental variants in escape genes are not only an
important cause of X-linked ID in female patients, but can result in
skewing as well.
Variants that Likely Cause XLID
In patients 5 and 6, we detected variants that likely caused XLID
but did not affect the X-inactivation pattern. These two patients
harbor variants in NHS andMECP2, respectively. In both cases, we
speculate that these variants are located on their active X chromo-
somes because their clinical features are similar to those observed
in male patients with variants in these genes, but more severe than
in other reported carrier female patients [Li et al., 2015; Lundvall
et al., 2006].
Variants that Likely Cause Skewing
Patients 7 and 8 harbor variants inMED12 and HDAC8, respec-
tively. In bothpatients, the variants are locatedon their preferentially
inactivated X-chromosomes, which is in line with reported data
where female patients tend to skew against mutations in these genes
[Kaiser et al., 2014; Risheg et al., 2007]. Escape of X-inactivation
was not observed for either variant. We therefore speculate that in
both patients, these variants caused preferential X-inactivation in
favor of the normal X chromosome. It is of note that the pattern
of skewing observed in peripheral blood cells may not be repre-
sentative for other tissues. Therefore, the XCI pattern in the brain
could be random and lead to a phenotype and although unlikely we
cannot unequivocally exclude a role for these variants in their ID
phenotypes. An overview of the variants detected in MED12 and
HDAC8 together with information on XCI are provided in Supp.
Table S5 and Supp. Table S6, respectively.
Autosomal Causes of ID
Additionally, we also found variants in autosomal ID genes in
two females with skewing, demonstrating that skewing can occur
independently from ID as well. However, an influence of autosomal
variants on the X-inactivation process cannot be excluded. Patient
9 presents with a Rubinstein–Taybi syndrome (RSTS)-like pheno-
type and harbors an in-frame deletion of 12 nucleotides in EP300.
Sincemutations in EP300 are responsible for roughly 8% of patients
with RSTS (MIM# 613684) with amilder phenotype [Rusconi et al.,
2015], we believe this novel EP300 variant on chromosome 22 is re-
sponsible for her ID aswell as other clinical features. Patient 10 had a
nonsynonymous variant (p.S1165L) in SYNGAP1 on chromosome
6. Mutations in SYNGAP1 are known to cause autosomal dominant
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Table 3. Basic Mechanisms of the Genetic Causes of XLID in
Female Patients with Skewing
Skewing XLID
One-hit model 1. Mutation in XLID gene that escapes XCI and causes skewing (on
Xa/Xi)
2. Mutation in XLID gene with insufficient skewing to rescue
complete phenotype
3. Chance Mutation in XLID gene that
does not affect XCI (on Xa)
Mutation in XLID gene that
escapes XCI and does not
affect XCI (on Xa/Xi)
Two-hit model Mutation causing skewing (Xi) Mutation in XLID gene (on
Xa)
Mutation causing skewing (Xi) Mutation in XLID gene that
escapes XCI (on Xa/Xi)
Mutation in XCI machinery
(on Xa/Xi)
Mutation in XLID gene
(on Xa)
Mutation in XLID gene that
escapes XCI (on Xa/Xi)
Mechanisms relying on secondary skewing are shaded in gray and mechanisms caused
by primary skewing are not highlighted. Xa, active X chromosome; Xi, inactive X
chromosome.
nonsyndromic ID (MIM# 612621), which is similar to the pheno-
type of patient 10. Other causal variants identified in SYNGAP1
are summarized in Supp. Table S7. In the same patient, we also de-
tected an indel over the exon–intron boundary in TAF9B, located
on Xq21.1. TAF9B is a core promoter factor and regulates neuronal
gene expression [Herrera et al., 2014]. To our knowledge, this is the
first report of a TAF9B variant in a patient and we speculate that the
TAF9B variant may be responsible for skewing, although a modifier
effect on the phenotype cannot be excluded.
Potential Mechanisms of the Genetic Causes of ID in
Female Patients with Skewing
There are several mechanisms that could lead to XLID in female
patients with skewing. These potentialmechanisms are summarized
in Table 3. The first possibility is that only one X-linked gene is af-
fected. In this one-hit model, there are three possibilities: First,
the mutation causing the phenotype also influences the inactiva-
tion process of that X-chromosome. For example, escape of X-
inactivation is often partial and incomplete with a lower expression
from the allele located on the inactive X chromosome. Cells with the
mutation on their inactive X chromosomes could therefore have a
growth advantage in comparison to cells with the mutation on their
active X chromosomes [Miyake et al., 2013]. In our cohort, potential
variants that fall into this category were detected in the escape genes
DDX3X and SMC1A and in the non-escape geneWDR45. Another
mechanism where one hit can be responsible for ID as well as skew-
ing is illustrated by X:autosome translocations with the breakpoint
in anXLIDgene.Here, the selection is against the normalX chromo-
some in 95% of cases because if the derivative X chromosome were
to be inactivated, then genes in the translocated autosomal region
would also be inactivated.Hence, the female canpresentwith the full
blown phenotype that is also seen in males carrying a mutation in
that gene [Frints et al., 2008; Hagens et al., 2006]. Second, cells with
the mutation are only viable in case of extreme (but not complete)
secondary skewing against this mutation with the prime example
of incontinentia pigmenti (MIM# 308300) [Woffendin et al., 1999].
Third, a mutation causing ID can be accompanied by skewing that
had occurred by chance.
The second possibility is that mutations are present in two genes
(two-hitmodel). The effects of these twomutations can be indepen-
dent of each other, for example, a mutation in an autosomal gene
causes ID and amutation in an X-linked gene causes skewing. How-
ever, one mutationmight have an influence on the expression of the
other such that one mutation causes skewing and forces a second
X-linked mutation, responsible for ID, to be expressed. Most likely
the twomutations are located ondifferentX chromosomes although
it is also possible that they both reside on the same X chromosome
as inactivating mutations in XIST can render that X chromosome
incapable of being inactivated [Penny et al., 1996]. Another as-
pect to take into account is that if the second ID-causing mutation
is in an escape gene, then it can also cause XLID irrespective of
whether it is located on the active X or not [Miyake et al., 2013].
Recently, female patients with mutations in X-linked genes and pre-
senting with predominant X-inactivation of the apparent normal X
chromosome have been reported for multiple disorders. These in-
cludeMECP2 duplication [Fieremans et al., 2014], Wiskott-Aldrich
syndrome (MIM# 614493) [Boonyawat et al., 2013; Daza-Cajigal
et al., 2013], Duchenne muscular dystrophy (MIM# 310200) [Juan-
Mateu et al., 2012], Fabry disease (MIM# 301500) [Bouwman et al.,
2011], and mucopolysaccharidosis type II (MIM# 309900) [Kloska
et al., 2011; Pina-Aguilar et al., 2013]. These findings strongly sug-
gest that this “female X-linked two-hit model” can result in several
X-linked conditions. In patients 5–10, we expect the variant respon-
sible for ID to be different from the variant causing skewing. We
therefore expect two different mutations to be required to cause
both ID and skewing in these patients. However, we did not identify
two different potential harmful X-linked variants in any of these
patients. This inability could be due to the limitations of exome se-
quencing if, for example, the variant is located in distant regulatory
elements, or these apparently missed variants may not have been
predicted to be detrimental based on current detection pipelines.
Finally, unknown mechanisms might obscure our current way of
thinking.
In this study,we identified anX-linked cause for ID in six out of 19
female patients with extremeX-inactivation. A yield of roughly 30%
is very high compared with previous large-scale exome sequenc-
ing studies on thousands of samples in which the contribution of
disease-causing variants on the X chromosome ranged from 2.5%
to 17% [DDD2015; de Ligt et al., 2012; Gilissen et al., 2014; Grozeva
et al., 2015; Hamdan et al., 2014; Rauch et al., 2012; Redin et al.,
2014; Tzschach et al., 2015; Vissers et al., 2010; Yang et al., 2014]. If
autosomal causes of ID are included, we detected a disease-causing
variant in eight out of 19 patients. An overall diagnostic yield of ap-
proximately 40% is well in line with previous data where diagnostic
yields of up to 42% were also obtained through whole exome and
whole genome sequencing analyses [DDD 2015; de Ligt et al., 2012;
Gilissen et al., 2014; Grozeva et al., 2015; Hamdan et al., 2014; Redin
et al., 2014]. On the other hand, Hu et al. (2015) predicted that
the X-exome sequencing of XLID families may resolve up to 58%
of Fragile X-negative males, which is almost double the amount of
resolved cases in our female cohort. However, considering the small
number of samples in our cohort, and due to the differences in study
design, inclusion criteria and the fact that studies were performed
on patient cohorts consisting mainly of males, these numbers can-
not be directly compared. Also, considering that X-linked forms of
ID are thought to account for 5%–10% of ID in all male patients
[Lubs et al., 2012], a yield of 30% causal X-linked variants in female
patients with skewing shows that skewing is in fact a good indicator
of an underlying X-linked defect. Although we did not investigate
the frequency of mutations in XLID genes in an unselected cohort
of female patients with syndromic ID, we believe that the rate of
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establishing an etiological molecular diagnosis will be substantially
lower than in our female cohort.
De novo events appear to be an important cause of ID in our
cohort considering that all of the variants where parental DNA was
available have occurred de novo. These results are similar to WES
studies on mixed gender samples where 39%–55% of severe ID
cases, not including CNV’s, were shown to be caused by de novo
events [Gilissen et al., 2014; Rauch et al., 2012]. This high incidence
of de novo variants is not surprising as our cohort consisted solely
of sporadic patients with ID. De novo events are an important cause
for skewing as well and we did not detect any inherited variants
responsible for either primary or secondary skewing. Interestingly,
in the two mothers with XCI patterns >80%, the cause for skewing
in their daughters was de novo.
Our data strongly suggest that severe skewing of X-inactivation
in female ID patients is a good indicator for a causal variant in an
X-linked gene. Moreover, unfavorable X-inactivation patterns can
contribute to the severity of the disease phenotype and therefore,
XCI analysis in female patients can help to unravel the modifying
effect of XCI in females with X-linked disorders.
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